<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270786</url>
  </required_header>
  <id_info>
    <org_study_id>2019-BMT-Antibio</org_study_id>
    <nct_id>NCT04270786</nct_id>
  </id_info>
  <brief_title>Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever</brief_title>
  <official_title>Phase III Randomized Study of Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever in Patients Undergoing Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized study to evaluate the safety and feasibility of early de-escalation of
      empirical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem
      cell transplantation (HSCT). In case of afebrile for 72 hours with empirical antibiotics
      treatment, patients will be randomized into 2 groups. In the early de-escalation group,
      antibiotics treatment will be stopped and prophylaxis with levofloxacin will be resumed. In
      the control group, the empirical treatment will continue until recovery of neutropenia or at
      least for 7 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized study to evaluate the safety and feasibility of early de-escalation
      treatment of empyrical antibiotics treatment in neutropenic fever patients undergoing
      hematopoietic stem cell transplantation (HSCT). All patients undergoing HSCT will receive
      levofloxacin as regular prophylaxis. After patients develop neutropenia fever, the empirical
      antibiotics protocol will be impenem. In case of persistent for 48 hours, vancomycin will be
      added. If afebrile is achieved for 72 hours, all patients will randomized into early
      de-escalating group or control group. In de-escalating group, the empirical antibiotics
      treatment will be stopped and then levofloxacin prophylaxis will be resumed. In the control
      group, the empirical antibiotics treatment will be continue until recovery of neutropenia or
      at least 7 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days of no empirical antibiotics treatment</measure>
    <time_frame>28 days</time_frame>
    <description>days from start of empirical antibiotics to end of study minus days with empirical antibiotics</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Early de-escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the experiment arm, empirical antibiotics will be stopped and levofloxacin prophylaxis will be resumed in case of afebrile after 72 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>In the control group, empirical antibiotics will be continue until recovery of neutropenia or at least 7 days as standard clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Early de-escalation</intervention_name>
    <description>In de-escalating group, the empirical antibiotics will be stopped and then prophylaxis levofloxacin will be resumed.</description>
    <arm_group_label>Early de-escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard</intervention_name>
    <description>In the control arm, empirical antibiotics will be continue until recpvery of neutropenia or at least 7 days after afebrile.</description>
    <arm_group_label>Standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18，patients undergo hematopoietic stem cells

          -  Patients with neutropenic fever: T≥38.5°C once or T≥38°C twice a day with ANC
             &lt;0.5x109/L or predicted to be &lt;0.5x109/L in 24 ~48 hours；

          -  Patients achieved afebrile （T&lt;37.5°C）for at least 72 hours；

          -  Inform consent given

        Exclusion Criteria:

          -  Patients with neutropenic fever with documented blood stream infection, skin and soft
             tissue infection, pneumonia and catheter associated infection.

          -  Patients with septic shock

          -  Levofloaxin allergy or contra-indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiong hu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ling Wang</last_name>
    <phone>86-21-64370045</phone>
    <phone_ext>601878</phone_ext>
    <email>cclingjar@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiong HU</last_name>
    <phone>86-21-64370045</phone>
    <email>hj10709@rjh.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiong HU, M.D.,</last_name>
      <phone>86-21-64370045</phone>
      <email>hujiong@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Ling Wang, M.D.,</last_name>
      <phone>86-21-64370045</phone>
      <email>cclingjar@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood and Marrow Transplantation Center, Rui Jin Hospital</investigator_title>
  </responsible_party>
  <keyword>neutropenic fever, empiric, antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

